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ASTROESOPHAGEAL  REFLUX  DISEASE 
(GERD)  is  common  in  affluent  societies, 
and its prevalence is also on the rise in de-
veloping  regions  such  as  Southeast  Asia.1  When 
heartburn  and  regurgitation  are  the  dominant 
symptoms, a diagnosis  of  GERD can  be  made.2  In 
primary care, patients are often treated empirically; 
treatment choices are driven  largely  by symptoms, 
with  the  aim  of  reducing  those  symptoms  to  the 
point  where they become  minimal  or  disappear.  A 
considerable  proportion  of patients  undergo  endo-
scopy during their “GERD career.” In part, the use 
of  endoscopy  is  motivated  by  concerns  about  Bar-
rett’s esophagus, a condition associated with an in-
creased  risk  of  adenocarcinoma  of  the  distal 
esophagus. Both Barrett’s esophagus and the rising 
prevalence of esophageal adenocarcinoma in  afflu-
ent societies are clearly associated with GERD.3 
  It is estimated that only 20%–40% of symptomatic 
patients with GERD will have endoscopic evidence of 
esophagitis.4  Naturally,  when  esophagitis  is  found, 
another  important  aim  of  therapy  is  healing  of  the 
mucosa. There is reasonable evidence that in patients 
with  reflux  esophagitis  the  disappearance  of  symp-
toms is associated with endoscopically demonstrated 
healing  of  the  esophagitis.  Thus,  the  aims  of  treat-
ment  in  patients  with  GERD  are  symptom  control 
and the healing of esophagitis where it occurs. 
  There is overwhelming evidence that acid suppres-
sion with either a proton pump inhibitor (PPI) or a 
histamine-2 (H2) receptor antagonist should be used 
as the  mainstay  of  GERD  treatment,  and that PPIs 
are clearly superior to H2-receptor antagonists. Over 
the years, prokinetic agents have also been evaluated 
for  the  treatment  of  GERD  and  dyspepsia.  Their 
mode of action includes improvement of lower eso-
phageal  sphincter  function,  improvement  of  eso-
phageal  motility, and acceleration of gastric empty-
ing.  Most  studies  were  conducted  with  cisapride,  a 
drug  that  has  been  withdrawn  from  most  markets 
because of the rare but serious side effect of cardiac 
arrhythmias sometimes resulting in death.5 Prokinet-
ics have  been evaluated in the treatment of GERD, 
and the question is whether there is indeed sufficient 
evidence of their effectiveness. Studies have included 
a comparison of the active drug to placebo, and com-
parison of the use of prokinetic agents with an acid-
suppressive  agent  versus  use  of  the  anti-secretory 
agent alone. 
  Manzotti and colleagues6 report in Open Medicine 
the  findings  of  a  systematic  review  in  which  they 
evaluate the use of prokinetic agents in the treatment 
of reflux esophagitis. The two main outcomes of in-
terest were improvement of symptoms and healing of 
esophageal  inflammation.  The  methodology  is  well 
laid out, and the authors report that 18 publications 
fulfilled their criteria for review. Of these, 8 studies 
assessed  only  symptom  improvement,  5  assessed 
only endoscopic improvement, and 6 reported both 
outcomes. 
  The  9  studies  reporting  symptom  outcomes  for 
which data could be pooled used a variety of scales, 
which for the systematic review had to be transformed 
into a measure of “improved” versus “not improved.” 
It is important to keep in mind that any transforma-
tion  of  scales  runs  the  risk  of  losing  information. 
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Compared with placebo, prokinetic agents (total sam-
ple size 379 patients) offered a significant benefit with 
regard to symptom improvement, with a relative risk 
(RR) of 1.7 (95% confidence interval [CI] 1.37–2.12) 
and  an  absolute  risk  reduction  of  30%.  However,  a 
funnel plot shows asymmetry, suggesting that the re-
sults were not consistent from study to study. Simi-
larly, the pooled results of the 11 studies that reported 
endoscopic healing or improvement (total sample size 
887 patients) showed significant heterogeneity and a 
small  effect size, with  an  RR  of  1.26  (95%  CI  1.03–
1.53) and an absolute risk difference of 16%. When the 
analysis was limited to complete endoscopic healing, 
the results were no longer statistically significant (RR 
1.36, 95% CI 0.97–1.89); again, the data demonstrated 
significant heterogeneity. 
  The authors assessed the quality of the studies in-
cluded  in  their  systematic  review  using  a  modified 
Jadad score, which has a range from 0–8. Only two 
studies had a score of 7 or 8; the remainder scored 4 
or  5,  indicating  that  the  average  study  quality  was 
moderate at best. We suggest that the results of the 
analysis should be viewed far more tentatively than 
the authors suggest, for the following reasons: 
1.   There  is  general  agreement  that  the  important 
outcomes in esophagitis trials are complete heal-
ing of the esophageal mucosa and complete reso-
lution of symptoms.7 
2.   Only six of the studies reported both outcomes, 
and  many  of  the  studies  were  of  poor  quality.  
This  is  reflected  by  their  intermediate  quality 
scores; their low sample sizes (only 3 studies in-
cluding more than 100 patients); and the low im-
pact factor of the journals in which many of the 
studies  were  published.  For  a  well-established 
clinical  entity  such  as  reflux  esophagitis,  high-
quality studies should be the norm. 
3.   Other systematic reviews have come to a less op-
timistic  conclusion  that  that  drawn  by  Manzotti 
and colleagues. A Cochrane review by Khan and 
colleagues, in which only 3 randomized controlled 
trials, involving a total of 198 patients, met the in-
clusion criteria, found a non-significant benefit of 
prokinetic agents in healing esophagitis (RR 0.71, 
95%  CI  0.46–1.10).8  Another  systematic  review, 
cited by Manzotti and colleagues, evaluated symp-
tomatic treatment (meaning that it is not known 
whether these patients had esophagitis) and iden-
tified  only  1  study  that  evaluated  cisapride  (RR 
0.86,  95%  CI  0.73–1.01).9  More  importantly,  in 
this review the relative risk of symptom improve-
ment was markedly lower than observed for PPIs 
(RR 0.37) and somewhat lower than for H2 block-
ers (RR 0.77). 
4.   The main analysis included not only studies that 
combined  comparisons  of  the  prokinetic  agents 
versus  placebo,  but  also  trials  that  combined 
prokinetic  agents  with  an  H2  blocker  and  then 
compared the results to placebo. Although the di-
rection of the results was the same in both groups 
of  studies  when  they  were  analyzed  separately, 
we believe that clinical evidence for combination 
therapy should not be considered as evidence for 
the use of the prokinetic agent alone. 
  Does study quality matter?  It certainly does. Cis-
apride  has  also  been  extensively  evaluated  in  the 
treatment of non-ulcer dyspepsia, that is, in patients 
whose  endoscopic  findings  were  normal.  A  system-
atic review clearly demonstrated that studies with a 
low Jadad quality score showed a higher effect size 
than studies with a high Jadad score.10  
  In  summary,  we  believe  that  questions  remain 
about  proof  of  efficacy  with  regard  to  healing  of 
esophagitis  and  symptom  improvement  for  proki-
netic agents used in the treatment  of reflux esoph-
agitis. The study methodology for such trials is well 
established  and  should  report  of  healing  of  esoph-
agitis and complete resolution of symptoms. Any fu-
ture use of prokinetic agents in GERD should be sub-
jected  to  high-quality  randomized  trials  with  ade-
quate sample sizes and should be compared against 
the current gold standard of PPI therapy. 
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